GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

Abstract Background The cure rate for metastatic osteosarcoma has not substantially improved over the past decades. Clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab for metastatic or refractory osteosarcoma were not successful, and neither was immune checkpoint inhibitors (ICIs). Met...

Полное описание

Библиографические подробности

Главные авторы:	Jeong A. Park, Nai-Kong V. Cheung
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2020-12-01
Серии:	Journal of Hematology & Oncology
Предметы:	Osteosarcoma Immunotherapy Bispecific antibody Disialogangliosides Human epidermal growth factor receptor-2 T cell arming
Online-ссылка:	https://doi.org/10.1186/s13045-020-01012-y
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!